PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment

Dimitrios Mathios, Jacob Ruzevick, Christopher M. Jackson, Haiying Xu, Sagar Shah, Janis M. Taube, Peter C. Burger, Edward F. McCarthy, Alfredo Quinones-Hinojosa, Drew M. Pardoll, Michael Lim

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Chordomas are rare malignant tumors that are postulated to arise from remnants of the notochord. Currently, the interaction between chordomas and the host immune system is poorly understood. The checkpoint protein, PD-1 is expressed by circulating lymphocytes and is a marker of activation and exhaustion. Its ligands, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), are expressed on a variety of human cancers; however this pathway has not been previously reported in chordomas. We used flow cytometric and RT-PCR analysis in three established primary and recurrent chordoma cell lines (U-CH1, U-CH2, and JHC7) as well as immunohistochemical analysis of chordoma tissues from 10 patients to identify and localize expression of PD-1 pathway proteins. PD-1 ligands are not constitutively expressed by chordoma cells, but their expression is induced in the setting of pro-inflammatory cytokines in all cell lines examined. In paraffin embedded tissues, we found that tumor infiltrating lymphocytes expressed PD-1 in 3/6 cases. We also found that, although chordoma cells did not express significant levels of PD-L1, PD-L1 expression was observed on tumor-infiltrating macrophages and tumor infiltrating lymphocytes. Our study suggests that PD-1, PD-L1, and PD-L2 are present in the microenvironment of a subset of chordomas analyzed. Future studies are needed to evaluate the contribution of the PD-1 pathway to the immunosuppressive microenvironment of chordomas.

Original languageEnglish (US)
Pages (from-to)251-259
Number of pages9
JournalJournal of Neuro-Oncology
Volume121
Issue number2
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Chordoma
Tumor-Infiltrating Lymphocytes
Ligands
Notochord
Cell Line
Neoplasms
Immunosuppressive Agents
Paraffin
Immune System
Proteins
Macrophages
Lymphocytes
Cytokines
Polymerase Chain Reaction

Keywords

  • B7-H1
  • Chordomas
  • PD-1
  • PD-L1
  • PD-L2

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Mathios, D., Ruzevick, J., Jackson, C. M., Xu, H., Shah, S., Taube, J. M., ... Lim, M. (2015). PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. Journal of Neuro-Oncology, 121(2), 251-259. https://doi.org/10.1007/s11060-014-1637-5

PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. / Mathios, Dimitrios; Ruzevick, Jacob; Jackson, Christopher M.; Xu, Haiying; Shah, Sagar; Taube, Janis M.; Burger, Peter C.; McCarthy, Edward F.; Quinones-Hinojosa, Alfredo; Pardoll, Drew M.; Lim, Michael.

In: Journal of Neuro-Oncology, Vol. 121, No. 2, 2015, p. 251-259.

Research output: Contribution to journalArticle

Mathios, D, Ruzevick, J, Jackson, CM, Xu, H, Shah, S, Taube, JM, Burger, PC, McCarthy, EF, Quinones-Hinojosa, A, Pardoll, DM & Lim, M 2015, 'PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment', Journal of Neuro-Oncology, vol. 121, no. 2, pp. 251-259. https://doi.org/10.1007/s11060-014-1637-5
Mathios D, Ruzevick J, Jackson CM, Xu H, Shah S, Taube JM et al. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. Journal of Neuro-Oncology. 2015;121(2):251-259. https://doi.org/10.1007/s11060-014-1637-5
Mathios, Dimitrios ; Ruzevick, Jacob ; Jackson, Christopher M. ; Xu, Haiying ; Shah, Sagar ; Taube, Janis M. ; Burger, Peter C. ; McCarthy, Edward F. ; Quinones-Hinojosa, Alfredo ; Pardoll, Drew M. ; Lim, Michael. / PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. In: Journal of Neuro-Oncology. 2015 ; Vol. 121, No. 2. pp. 251-259.
@article{f828266cf2c14fadae367ae306bc0369,
title = "PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment",
abstract = "Chordomas are rare malignant tumors that are postulated to arise from remnants of the notochord. Currently, the interaction between chordomas and the host immune system is poorly understood. The checkpoint protein, PD-1 is expressed by circulating lymphocytes and is a marker of activation and exhaustion. Its ligands, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), are expressed on a variety of human cancers; however this pathway has not been previously reported in chordomas. We used flow cytometric and RT-PCR analysis in three established primary and recurrent chordoma cell lines (U-CH1, U-CH2, and JHC7) as well as immunohistochemical analysis of chordoma tissues from 10 patients to identify and localize expression of PD-1 pathway proteins. PD-1 ligands are not constitutively expressed by chordoma cells, but their expression is induced in the setting of pro-inflammatory cytokines in all cell lines examined. In paraffin embedded tissues, we found that tumor infiltrating lymphocytes expressed PD-1 in 3/6 cases. We also found that, although chordoma cells did not express significant levels of PD-L1, PD-L1 expression was observed on tumor-infiltrating macrophages and tumor infiltrating lymphocytes. Our study suggests that PD-1, PD-L1, and PD-L2 are present in the microenvironment of a subset of chordomas analyzed. Future studies are needed to evaluate the contribution of the PD-1 pathway to the immunosuppressive microenvironment of chordomas.",
keywords = "B7-H1, Chordomas, PD-1, PD-L1, PD-L2",
author = "Dimitrios Mathios and Jacob Ruzevick and Jackson, {Christopher M.} and Haiying Xu and Sagar Shah and Taube, {Janis M.} and Burger, {Peter C.} and McCarthy, {Edward F.} and Alfredo Quinones-Hinojosa and Pardoll, {Drew M.} and Michael Lim",
year = "2015",
doi = "10.1007/s11060-014-1637-5",
language = "English (US)",
volume = "121",
pages = "251--259",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment

AU - Mathios, Dimitrios

AU - Ruzevick, Jacob

AU - Jackson, Christopher M.

AU - Xu, Haiying

AU - Shah, Sagar

AU - Taube, Janis M.

AU - Burger, Peter C.

AU - McCarthy, Edward F.

AU - Quinones-Hinojosa, Alfredo

AU - Pardoll, Drew M.

AU - Lim, Michael

PY - 2015

Y1 - 2015

N2 - Chordomas are rare malignant tumors that are postulated to arise from remnants of the notochord. Currently, the interaction between chordomas and the host immune system is poorly understood. The checkpoint protein, PD-1 is expressed by circulating lymphocytes and is a marker of activation and exhaustion. Its ligands, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), are expressed on a variety of human cancers; however this pathway has not been previously reported in chordomas. We used flow cytometric and RT-PCR analysis in three established primary and recurrent chordoma cell lines (U-CH1, U-CH2, and JHC7) as well as immunohistochemical analysis of chordoma tissues from 10 patients to identify and localize expression of PD-1 pathway proteins. PD-1 ligands are not constitutively expressed by chordoma cells, but their expression is induced in the setting of pro-inflammatory cytokines in all cell lines examined. In paraffin embedded tissues, we found that tumor infiltrating lymphocytes expressed PD-1 in 3/6 cases. We also found that, although chordoma cells did not express significant levels of PD-L1, PD-L1 expression was observed on tumor-infiltrating macrophages and tumor infiltrating lymphocytes. Our study suggests that PD-1, PD-L1, and PD-L2 are present in the microenvironment of a subset of chordomas analyzed. Future studies are needed to evaluate the contribution of the PD-1 pathway to the immunosuppressive microenvironment of chordomas.

AB - Chordomas are rare malignant tumors that are postulated to arise from remnants of the notochord. Currently, the interaction between chordomas and the host immune system is poorly understood. The checkpoint protein, PD-1 is expressed by circulating lymphocytes and is a marker of activation and exhaustion. Its ligands, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), are expressed on a variety of human cancers; however this pathway has not been previously reported in chordomas. We used flow cytometric and RT-PCR analysis in three established primary and recurrent chordoma cell lines (U-CH1, U-CH2, and JHC7) as well as immunohistochemical analysis of chordoma tissues from 10 patients to identify and localize expression of PD-1 pathway proteins. PD-1 ligands are not constitutively expressed by chordoma cells, but their expression is induced in the setting of pro-inflammatory cytokines in all cell lines examined. In paraffin embedded tissues, we found that tumor infiltrating lymphocytes expressed PD-1 in 3/6 cases. We also found that, although chordoma cells did not express significant levels of PD-L1, PD-L1 expression was observed on tumor-infiltrating macrophages and tumor infiltrating lymphocytes. Our study suggests that PD-1, PD-L1, and PD-L2 are present in the microenvironment of a subset of chordomas analyzed. Future studies are needed to evaluate the contribution of the PD-1 pathway to the immunosuppressive microenvironment of chordomas.

KW - B7-H1

KW - Chordomas

KW - PD-1

KW - PD-L1

KW - PD-L2

UR - http://www.scopus.com/inward/record.url?scp=84925467372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925467372&partnerID=8YFLogxK

U2 - 10.1007/s11060-014-1637-5

DO - 10.1007/s11060-014-1637-5

M3 - Article

C2 - 25349132

AN - SCOPUS:84925467372

VL - 121

SP - 251

EP - 259

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -